The DOI matches its Crossref record; 32 of the 32 references it cites were found in a registry or an index.
Effect of aldose reductase inhibition on nerve conduction and morphometry in diabetic neuropathy
Abstract
OBJECTIVE: To determine whether the aldose reductase inhibitor (ARI) zenarestat improves nerve conduction velocity (NCV) and nerve morphology in diabetic peripheral polyneuropathy (DPN). METHODS: A 52-week, randomized, placebo-controlled, double-blinded, multiple-dose, clinical trial with the ARI zenarestat was conducted in patients with mild to moderate DPN. NCV was measured at baseline and study end. Contralateral sural nerve biopsies were obtained at 6 weeks and at the study's end for nerve sorbitol measurement and computer-assisted light morphometry to determine myelinated nerve fiber density (number of fibers/mm2 cross-sectional area) in serial bilateral sural nerve biopsies. RESULTS: Dose-dependent increments in sural nerve zenarestat level and sorbitol suppression were accompanied by significant improvement in NCV. In a secondary analysis, zenarestat doses producing >80% sorbitol suppression were associated with a significant increase in the density of small-diameter (<5 microm) sural nerve myelinated fibers. CONCLUSIONS: Aldose reductase pathway inhibition improves NCV slowing and small myelinated nerve fiber loss in DPN in humans, but >80% suppression of nerve sorbitol content is required. Thus, even low residual levels of aldose reductase activity may be neurotoxic in diabetes, and potent ARIs such as zenarestat may be required to stop or reverse progression of DPN.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
(1993) · New England Journal of Medicine · doi:10.1056/nejm199309303291401 · Cited by 24,667
Young, M. J., Boulton, A. J. M., Macleod, A. F., Williams, D. R. R., & Sonksen, P. H. (1993) · Diabetologia · doi:10.1007/bf00400697 · Cited by 1,502
Pirart, J. (1978) · Diabetes Care · doi:10.2337/diacare.1.3.168 · Cited by 1,290
Williams, D. A. (1971) · Biometrics · doi:10.2307/2528930 · Cited by 775
The Comparison of Several Dose Levels with a Zero Dose Control
Williams, D. A. (1972) · Biometrics · doi:10.2307/2556164 · Cited by 752
Natural History of Peripheral Neuropathy in Patients with Non-Insulin-Dependent Diabetes Mellitus
Partanen, J., Niskanen, L., Lehtinen, J., Mervaala, E., Siitonen, O., & Uusitupa, M. (1995) · New England Journal of Medicine · doi:10.1056/nejm199507133330203 · Cited by 656
The Effect of Intensive Diabetes Therapy on the Development and Progression of Neuropathy
The Diabetes Control and Complications Trial Research Group. (1995) · Annals of Internal Medicine · doi:10.7326/0003-4819-122-8-199504150-00001 · Cited by 602
Self-citationCLINICAL AND NEUROPATHOLOGICAL CRITERIA FOR THE DIAGNOSIS AND STAGING OF DIABETIC POLYNEUROPATHY
DYCK, P. J., KARNES, J. L., DAUBE, J., O'BRIEN, P., & SERVICE, F. J. (1985) · Brain · doi:10.1093/brain/108.4.861 · Cited by 326
Aldose Reductase Inhibition Improves Nerve Conduction Velocity in Diabetic Patients
Judzewitsch, R. G., Jaspan, J. B., Polonsky, K. S., Weinberg, C. R., Halter, J. B., Halar, E., Pfeifer, M. A., Vukadinovic, C., Bernstein, L., Schneider, M., et al. (1983) · New England Journal of Medicine · doi:10.1056/nejm198301203080302 · Cited by 313
Report and Recommendations of the San Antonio Conference on Diabetic Neuropathy
(1988) · Diabetes · doi:10.2337/diab.37.7.1000 · Cited by 308
Sima, A. A. F., Bril, V., Nathaniel, V., McEwen, T. A., Brown, M. B., Lattimer, S. A., & Greene, D. A. (1988) · New England Journal of Medicine · doi:10.1056/nejm198809013190905 · Cited by 293
Self-citationSima, A. A., Nathaniel, V, Bril, V, McEwen, T. A., & Greene, D. A. (1988) · Journal of Clinical Investigation · doi:10.1172/jci113327 · Cited by 217
Self-citationAldose reductase inhibitors and their potential for the treatment of diabetic complications
Tomlinson, D. R., Stevens, E. J., & Diemel, L. T. (1994) · Trends in Pharmacological Sciences · doi:10.1016/0165-6147(94)90010-8 · Cited by 186
Britland, S. T., Young, R. J., Sharma, A. K., & Clarke, B. F. (1990) · Diabetes · doi:10.2337/diab.39.8.898 · Cited by 166
The Aetiology of Diabetic Neuropathy: the Combined Roles of Metabolic and Vascular Defects
Stevens, M. J., Feldman, E. L., & Greene, D. A. (1995) · Diabetic Medicine · doi:10.1111/j.1464-5491.1995.tb00544.x · Cited by 158
Self-citationBoulton, A. J. M., Levin, S., & Comstock, J. P. (1990) · Diabetologia · doi:10.1007/bf00404095 · Cited by 137
Yagihashi, S., Kamijo, M., Ido, Y., & Mirrlees, D. J. (1990) · Diabetes · doi:10.2337/diab.39.6.690 · Cited by 110
Cameron, N. E., Cotter, M. A., & Hohman, T. C. (1996) · Diabetologia · doi:10.1007/bf00403960 · Cited by 97
Greene, D. A., & Winegrad, A. I. (1979) · Diabetes · doi:10.2337/diab.28.10.878 · Cited by 90
Self-citationNeuropathy and mortality in diabetes: Influence of pancreas transplantation
Navarro, X., Kennedy, W. R., Aeppli, D. M., & Sutherland, D. E. R. (1996) · Muscle & Nerve · Cited by 86
Ao, S., 新宮, 保., Kikuchi, C., Takano, Y., Nomura, K., Fujiwara, T., Ohkubo, Y., Notsu, Y., & Yamaguchi, I. (1991) · Metabolism · doi:10.1016/0026-0495(91)90196-4 · Cited by 73
Sima, A. A. F., Greene, D. A., Brown, M. B., Hohman, T. C., HICKS, D. R., Graepel, G. J., Bochenek, W. J., Beg, M. A., & Gonen, B. (1993) · Journal of Diabetes and its Complications · doi:10.1016/1056-8727(93)90041-v · Cited by 69
Self-citationJakobsen, J., Christiansen, J. S., Kristoffersen, I. B., Christensen, C., Hermansen, K., Schmitz, A., & Mogensen, C. E. (1988) · Diabetes · doi:10.2337/diab.37.4.452 · Cited by 68
Proceedings of a Consensus Development Conference on Standardized Measures in Diabetic Neuropathy
(1992) · Neurology · doi:10.1212/wnl.42.9.1823 · Cited by 66
Russell, J. W., Karnes, J. L., & Dyck, P. J. B. (1996) · Journal of the Neurological Sciences · doi:10.1016/0022-510x(95)00243-u · Cited by 62
Peripheral nerve function and metabolic control in diabetes mellitus
Troni, W., Carta, Q., Cantello, R. M., et al. (1984) · Annals of Neurology · doi:10.1002/ana.410160204 · Cited by 62
Florkowski, C. M., Rowe, B. R., Nightingale, S., Harvey, T. C., & Barnett, A. H. (1991) · Diabetes · doi:10.2337/diab.40.1.129 · Cited by 55
Llewelyn, J., Thomas, P. K., Gilbey, S. G., Watkins, P., & Muddle, J. R. (1988) · Diabetologia · doi:10.1007/bf00276850 · Cited by 52
Oxidative stress and antioxidant treatment in diabetic neuropathy
van Dam, P. S., & Bravenboer, B. (1997) · Neuroscience Research Communications · doi:10.1002/(sici)1520-6769(199707)21:1<13::aid-nrc203>3.0.co;2-p · Cited by 42
The Sorbinil Retinopathy Trial
Sorbinil Retinopathy Trial Research Group, & Sorbinil Retinopathy Trial Research Group. (1993) · Neurology · doi:10.1212/wnl.43.6.1141 · Cited by 40
Sima, A. A. F., Brown, M. B., Prashar, A., Chakrabarti, S., Laudadio, C., & Greene, D. A. (1992) · Diabetologia · doi:10.1007/bf00400485 · Cited by 34
Self-citationFailure of Improved Glycaemic Control to Reverse Diabetic Autonomic Neuropathy
Thomas's, S., & Diabetic Study Group (1986) · Diabetic Medicine · doi:10.1111/j.1464-5491.1986.tb00774.x · Cited by 27
Cited by
Biochemistry and molecular cell biology of diabetic complications
Brownlee, M. (2001) · Nature · doi:10.1038/414813a · Cited by 9,107
Oxidative Stress in the Pathogenesis of Diabetic Neuropathy
Vincent, A. M., Russell, J. W., Low, P., & Feldman, E. L. (2004) · Endocrine Reviews · doi:10.1210/er.2003-0019 · Cited by 982
Boulton, A. J. M., Malik, R. A., Arezzo, J. C., & Sosenko, J. M. (2004) · Diabetes Care · doi:10.2337/diacare.27.6.1458 · Cited by 913
Self-citationDiabetic neuropathy: Mechanisms to management
Edwards, J. L., Vincent, A. M., Cheng, H. T., & Feldman, E. L. (2008) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2008.05.005 · Cited by 790
Lifestyle intervention for pre-diabetic neuropathy
Smith, A. G., Russell, J., Feldman, E. L., Goldstein, J., Peltier, A., Smith, S., Hamwi, J., Pollari, D., Bixby, B., Howard, J., et al. (2006) · Diabetes Care · doi:10.2337/dc06-0224 · Cited by 585
Metadata
- Authors
- Greene, D. A., Arezzo, J. C., Brown, M. B., & the Zenarestat Study Group
- Venue
- Neurology
- Published
- 1999-08
- Volume
- 53
- Issue
- 3
- Pages
- 580-580
- ISSN
- 0028-3878 (ISSN-L)
- 1526-632X
- OpenAlex
- W2012373895
- Cited by
- 278
- References
- 32
- FWCI
- 4.67
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.